BG106065A - Method for the treatment of neurological or neuropsychiatric disorders - Google Patents

Method for the treatment of neurological or neuropsychiatric disorders

Info

Publication number
BG106065A
BG106065A BG106065A BG10606501A BG106065A BG 106065 A BG106065 A BG 106065A BG 106065 A BG106065 A BG 106065A BG 10606501 A BG10606501 A BG 10606501A BG 106065 A BG106065 A BG 106065A
Authority
BG
Bulgaria
Prior art keywords
neurological
treatment
neuropsychiatric disorders
formula
prophylaxis
Prior art date
Application number
BG106065A
Other languages
Bulgarian (bg)
English (en)
Inventor
Gregory WILLIS
Original Assignee
Clarencew Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/285,859 external-priority patent/US6310085B1/en
Application filed by Clarencew Pty Ltd filed Critical Clarencew Pty Ltd
Publication of BG106065A publication Critical patent/BG106065A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0618—Psychological treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Social Psychology (AREA)
  • Pathology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Pain & Pain Management (AREA)
  • Radiology & Medical Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
BG106065A 1996-10-04 2001-10-31 Method for the treatment of neurological or neuropsychiatric disorders BG106065A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO2745A AUPO274596A0 (en) 1996-10-04 1996-10-04 Method for the treatment of neurological or neuropsychiatric disorders
US09/285,859 US6310085B1 (en) 1997-10-03 1999-04-02 Method for the treatment of neurological or neuropsychiatric disorders
PCT/AU2000/000275 WO2000059504A1 (fr) 1996-10-04 2000-03-31 Methode de traitement de troubles neurologiques ou neuropsychiatriques

Publications (1)

Publication Number Publication Date
BG106065A true BG106065A (en) 2002-04-30

Family

ID=37945448

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106065A BG106065A (en) 1996-10-04 2001-10-31 Method for the treatment of neurological or neuropsychiatric disorders

Country Status (21)

Country Link
US (1) US20020068692A1 (fr)
EP (2) EP0964679A4 (fr)
JP (2) JP2001503394A (fr)
CN (1) CN1345238A (fr)
AU (3) AUPO274596A0 (fr)
BG (1) BG106065A (fr)
BR (1) BR0009524A (fr)
CA (2) CA2267381A1 (fr)
CZ (1) CZ20013487A3 (fr)
EE (1) EE200100511A (fr)
HU (1) HUP0200287A3 (fr)
IL (1) IL145696A0 (fr)
MA (1) MA25404A1 (fr)
MX (1) MXPA01009963A (fr)
NO (1) NO20014674D0 (fr)
NZ (1) NZ515023A (fr)
PL (1) PL350961A1 (fr)
SK (1) SK13862001A3 (fr)
TR (1) TR200102864T2 (fr)
WO (2) WO1998015267A1 (fr)
ZA (1) ZA200108592B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
US7417038B1 (en) 1998-10-15 2008-08-26 Imperial Innovations Limited Methods of treating cachexia
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
IL130171A (en) * 1999-05-27 2004-06-01 Neurim Pharma 1991 Melatonin for use in the prevention and treatment of tardive dyskinesia, pharmaceutical formulations comprising it and its use for the manufacture of medicaments
IL138825A (en) * 2000-10-03 2006-06-11 Neurim Pharma 1991 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
US7303869B2 (en) 2001-07-17 2007-12-04 Northwestern University Solid-phase reactions
US7485443B2 (en) 2001-07-17 2009-02-03 Northwestern University Solid-phase reactions
JP2005219511A (ja) * 2002-02-05 2005-08-18 Azumaya:Kk ハイジャク防止システムおよぴ防止方法
MX2007007836A (es) 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Metodo para estabilizar un farmaco anti-demencia.
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
GB0701970D0 (en) 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
US9827210B2 (en) * 2007-06-29 2017-11-28 Phovitreal Pty Ltd Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration
US9662347B2 (en) 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
US10736889B2 (en) * 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US9918980B2 (en) * 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
DK2701707T3 (da) * 2011-04-29 2020-11-02 Univ Rutgers Fremgangsmåde til behandling af dyskinesi
EP2713883B1 (fr) * 2011-05-31 2024-07-10 Clarencew Pty Ltd. Procédés pour prévenir et traiter des états neurologiques liés à la fonction motrice
WO2012166972A1 (fr) 2011-05-31 2012-12-06 Hdk Holdings, Llc Appareils d'émission de lumière pour traiter et/ou diagnostiquer des états neurologiques associés à la fonction motrice
GB201416017D0 (en) * 2014-09-10 2014-10-22 New Royal Holloway & Bedford An Anticonvulsant Compound
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
CN116354924B (zh) * 2021-12-27 2025-05-30 江苏恩华药业股份有限公司 一种2-咪唑酮衍生物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468391A (en) * 1982-06-25 1984-08-28 Ayerst, Mckenna & Harrison, Inc. Combination of β-adrenoceptor antagonists and anxiolytic agents
IL79264A0 (en) * 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US5093352A (en) * 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
US5283343A (en) * 1987-08-17 1994-02-01 Whitby Research, Inc. 2-aryl substituted N-acetyltryptamines and process of preparing such
EP0460212A4 (en) * 1989-09-15 1992-04-29 Donetsky Gosudarstvenny Meditsinsky Institut Imeni M.Gorkogo Device for correcting the emotional state of a person
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5046494A (en) * 1990-08-27 1991-09-10 John Searfoss Phototherapy method
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2689124A1 (fr) * 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
GB2282807A (en) * 1993-10-15 1995-04-19 Merck & Co Inc Tryptophan esters and amides as tachykinin receptor antagonists
GB9407919D0 (en) * 1994-04-21 1994-06-15 Glaxo Group Ltd Chemical compounds
EP0714663A3 (fr) * 1994-11-28 1997-01-15 Lilly Co Eli Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
FR2778662B1 (fr) * 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
WO1998015267A1 (fr) 1998-04-16
AUPO274596A0 (en) 1996-10-31
HUP0200287A2 (en) 2002-06-29
AU736005B2 (en) 2001-07-26
CZ20013487A3 (cs) 2003-04-16
WO2000059504A1 (fr) 2000-10-12
EP1189613A4 (fr) 2004-02-11
PL350961A1 (en) 2003-02-24
BR0009524A (pt) 2002-02-19
NO20014674L (no) 2001-09-26
ZA200108592B (en) 2002-10-18
NZ515023A (en) 2004-01-30
US20020068692A1 (en) 2002-06-06
IL145696A0 (en) 2002-06-30
CA2267381A1 (fr) 1998-04-16
TR200102864T2 (tr) 2002-03-21
AU782492B2 (en) 2005-08-04
MXPA01009963A (es) 2003-07-14
SK13862001A3 (sk) 2003-04-01
EE200100511A (et) 2002-12-16
JP2001503394A (ja) 2001-03-13
CA2366850A1 (fr) 2000-10-12
EP1189613A1 (fr) 2002-03-27
EP0964679A1 (fr) 1999-12-22
CN1345238A (zh) 2002-04-17
NO20014674D0 (no) 2001-09-26
AU3410200A (en) 2000-10-23
MA25404A1 (fr) 2002-04-01
JP2002541105A (ja) 2002-12-03
HUP0200287A3 (en) 2002-12-28
EP0964679A4 (fr) 2002-09-11
AU4372597A (en) 1998-05-05

Similar Documents

Publication Publication Date Title
BG106065A (en) Method for the treatment of neurological or neuropsychiatric disorders
NZ332780A (en) Substituted amines for the treatment of neurological and neuropsychiatric disorders
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
GR3032207T3 (en) 2-Bromomelatonin in the therapy of sleep disorders
GR3019179T3 (en) Flupirtine in combination with antiparkinsonica against muscle bracing
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
EP0460912A3 (en) Medicaments for the treatment of sexual disorder
UA41355C2 (uk) Засіб для лікування нейро-сніду
FR05C0027I2 (fr)
GB9212308D0 (en) Therapeutic compositions
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
IL126235A0 (en) Compounds with growth hormone releasing properties
IL142803A0 (en) Pharmaceutical compositions containing r-tofisopam
DK0583026T3 (fr)
MY110149A (en) Compounds for the treatment of neurodegenerative disorders
AP9200355A0 (en) "Therapeutic agent"
AU634003B2 (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
GR3018651T3 (en) Treatment of ocular hypertention with a synergistic combination
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
ZA924128B (en) New combination preparations for treatment of Parkinson's disease.
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
AU6678194A (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
NZ268039A (en) Use of efaroxan in treating parkinson's disease
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
AU6955294A (en) Agents for the prevention and treatment of parkinson's disease